Monopar Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 8.4 million compared to USD 10.52 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.83 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5981 USD | -8.13% | -20.25% | +75.81% |
05-09 | Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-16 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.81% | 11.36M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- MNPR Stock
- News Monopar Therapeutics Inc.
- Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023